"Focusing Capabilities on Developing Subsequent Pipeline Candidates"
Onconic Therapeutics announced on August 7 that it has received approval from the Korean Intellectual Property Office to extend the patent term for its new drug for gastroesophageal reflux disease, 'Jacubo'.
This patent extension applies to Jacubo's core compound patent, titled "Imidazo[1,2-a]pyridine Derivatives, Method for Preparing Same, and Use Thereof." The original patent was set to expire on July 5, 2036, but has now been extended by approximately four years and two months, to September 13, 2040. The Korean Intellectual Property Office recently made the extension official and published the decision in the government gazette.
The patent term extension registration system is designed to address the issue of reduced effective patent periods due to regulatory approval processes for pharmaceuticals. If certain requirements are met, the patent term can be extended by up to five years. This system is considered a key mechanism for protecting intellectual property and securing market competitiveness for new drug developers.
Jacubo is the 37th domestically developed new drug approved in Korea, with Onconic Therapeutics receiving approval in April of last year. As a P-CAB class gastric acid secretion inhibitor, it offers faster onset of action and superior nighttime acid control compared to conventional PPI-based treatments. Recently, its indications have been expanded to include gastric ulcers. Notably, less than a year after its launch in October of last year, Jacubo surpassed 10 billion KRW in quarterly prescription sales in the second quarter of this year.
A representative from Onconic Therapeutics stated, "With this patent extension, Jacubo will be able to maintain exclusive status in the domestic market until 2040. As the protection of our proprietary new drug has been strengthened, we plan to focus our capabilities on developing subsequent pipeline candidates."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
